Skip to content

Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00475202
Enrollment
Unknown
Registered
2007-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2007-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiogenesis, Diabetic Foot Ulcers, Hyperbaric Therapy

Brief summary

Diabetic foot ulcers are a major cause of morbidity and mortality, accounting for approximately two-thirds of all non-traumatic amputations performed in the United States. The cost of foot ulcers in diabetic patients averages almost $28,000 for the two years after diagnosis of the ulcer. Hyperbaric oxygen (HBO) serves as primary or adjunctive therapy for a diverse range of medical conditions. HBO also has been used as an adjunct to antibiotics, debridement, and revascularization in the therapy of chronic, nonhealing wounds associated with diabetes or non-diabetic vascular insufficiency. The aim of the study is to assess whether hyperoxia induced angiogenesis in diabetic patients with foot ulcers.

Interventions

None listed

Sponsors

Assaf-Harofeh Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* age 18 years or older, with type II diabetes suffering from foot ulcers admitted to the Institute of Hyperbaric Medicine and Wound Care Clinic at Assaf Harofeh Medical Center (Israel)

Exclusion criteria

* Patients having chest pathology incompatible with pressure changes, inner ear disease, or suffering from claustrophobia, will be excluded from the study. Patients with significant macrovascular disease, defined as obstruction of more than 50% in the femoral or the popliteal arteries, will also be excluded from the study.

Countries

Israel

Contacts

Primary ContactAlbert Rabinovitz, MD
alik.r75@mail.ru+972-546-396503

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026